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Background     
Low-dose CT (LDCT) screening detects early stage lung cancer and reduces mortality. We 




LungSEARCH was a national multicentre randomised trial. Current/former smokers with 
mild/moderate COPD were allocated (1:1) to have 5 years surveillance or not. Screened 
participants provided annual sputum samples for cytology and cytometry, and if abnormal were 
offered annual LDCT and autofluorescence bronchoscopy (AFB). Those with normal sputum 
provided annual samples. Primary endpoint was the percentage of lung cancers diagnosed at 
stage I/II (non-small cell) or limited disease (small cell). 
 
Results 
1568 individuals were randomised 2007-2011, from 10 UK centres. 85.2% of those screened 
provided an adequate baseline sputum sample. There were 42 lung cancers among 785 
screened and 36 among 783 controls. 54.8% (23/42) screened versus 45.2% (14/31) controls 
with known staging were diagnosed with early stage disease (one-sided p=0.24). Relative risk 
1.21 (95%CI 0.75-1.95) or 0.82 (95%CI 0.52-1.31) for early stage or advanced cancers 
respectively. Overall sensitivity for sputum (in those randomised to surveillance) was low 
(40.5%) and cumulative false-positive rate (FPR) 32.8%. 55% of cancers had normal sputum 
results throughout. Among sputum-positive individuals who had AFB, sensitivity was 45.5% and 




Our sequential strategy, using sputum cytology/cytometry to select high-risk individuals for AFB 










Lung cancer is associated with poor survival because most cases are diagnosed at a 
late stage. However, early detection with intended curative treatments can have an 80% 
one-year survival rate for stage I disease.[1] 
 
During the 2000s, several randomised trials were developed to evaluate low dose CT 
(LDCT).[2] Expected major issues with LDCT screening included affordability and high 
false-positive rates (which can be reduced through improved management of pulmonary 
nodules).[3] Furthermore, LDCT might miss early squamous cell tumours located in the 
central airways.[4] 
 
Two major LDCT trials (US National Lung Screening Trial [NLST] and the NELSON 
study) now show a clear reduction in lung cancer mortality among current/former 
smokers who had annual LDCT compared to either chest radiograph or no 
screening.[5,6] LDCT screening is recommended in the US,[7] and suggested for 
Europe.[8] However, uptake in the US is low (<5% of those eligible).[9,10] Our 
LungSEARCH study was developed in 2006, long before those two trials were 
published. We proposed a different strategy to make screening more efficient. Instead 
of offering a single screening test, we created a novel approach of sequential screening 
(using sputum and imaging), and in a particularly high-risk group, i.e. current/former 
smokers with chronic obstructive pulmonary disease (COPD), based on promising 
evidence for the component tests.  
 
COPD is correlated with lung cancer risk, and is an independent risk factor to smoking 
and other characteristics.[11-12] Decreasing lung function (using GOLD criteria) is 
associated with increasingly worse survival.[13-14] Therefore, targeted lung cancer 
screening among people with COPD is appealing.[11,15-17] 
 
Sputum cytology is a non-invasive and non-radiological test for lung disease, especially 
central airway tumours. Sample procurement can be done at home without specialist 
equipment. Many smokers (particularly those with COPD) produce more sputum, 
containing exfoliated cells from the bronchial tree. There is an established association 
between having abnormal sputum cytology and lung cancer,[18-19] although 
randomised trials of cytology failed to reduce lung cancer mortality.[20] However, 
modern cytology methods have better sensitivity. Another sputum test involves 
computer assisted image analysis (automated image cytometry), which quantitatively 
analyses the nuclear structure and DNA content of individual cells, distinguishing 
normal from suspicious cells.[21-23] In a large study of smokers, 80% of lung cancers 
with sputum samples had abnormal cytometry, compared to only 4% who had abnormal 
cytology.[21] We hypothesized that the high performance sensitivities expected using 
modern cytology/cytometry would miss few cancers as a first screening test. 
 
Autofluorescence bronchoscopy (AFB) is an optical imaging technique which compares 
fluorescence properties between normal and malignant/pre-malignant bronchial 
mucosa.[24-26] AFB has a sensitivity for early stage lung cancer of 44-82% compared 
with 9-58% using conventional white light bronchoscopy.[26] The sensitivity for 
detecting abnormal lesions could be twice greater using AFB with white light than white 
light alone.[27] In a prior study of individuals with pre-invasive lesions, 73% had ≥1 
high-grade lesion, and 1 in 6 of these lesions progressed to invasive carcinoma.[28,29] 
 
LungSEARCH evaluated sequential testing for detecting lung cancer in a high-risk 
group, in which a cheap first screen is used to select who is offered LDCT and AFB. To 






Design and participants 
 
LungSEARCH was a national multi-centre randomised trial. The objective was to 
examine whether annual surveillance of individuals at high-risk of lung cancer 
(current/ex-smokers with COPD) can lead to a shift in cancer stage at diagnosis.  
 
Participants were identified primarily from general practice. A research nurse visited 
each practice to perform an electronic search of their COPD register, and those 
potentially eligible were invited by telephone to attend for baseline assessments. We 
also approached participants within outpatient COPD or pulmonary rehabilitation 
hospital clinics in which the trial investigators worked. 
 
Baseline COPD (by spirometry) was classified according to GOLD criteria as mild 
(FEV1/FVC <70%; FEV1≥80% predicted) or moderate (FEV1/FVC <70%; FEV1 50-
80% predicted).[30,31] Those with mild-moderate COPD were eligible for the trial if they 
currently smoked, or were former smokers who had quit within 8 years (agreed by the 
investigators to still have a high risk of lung cancer), and both groups had ≥20 pack-
years and/or have smoked for ≥20 years (thresholds often used in studies at the time); 
no history of malignant disease during the previous 5 years; and without serious co-
morbidities. The trial had multi-centre ethics approval and participants gave written 




Participants were randomised (1:1) to have annual screening/surveillance or not 
(controls). Research nurses telephoned the Cancer Trials Centre, where the random 
allocation (minimisation) was performed by computer, stratified by location,10-year age 




Individuals in the control arm had no trial-specific procedures, but to encourage study 
continuation they were offered an exit chest radiography 5 years post-randomisation (or 
sooner if they withdrew earlier) if they had not developed lung cancer. This was also 
offered to the screened group. 
 
Individuals in the screened group had sputum cytology and cytometry as initial tests, 
and only those with abnormal findings were offered LDCT and AFB, expecting that 
these in combination would be better than either alone at finding cancer in the central 
(by AFB) and peripheral (by LDCT) airways (Appendix Figure 1). Appendix Texts 1-3 
describes the three component tests. Screened individuals posted sputum samples to 
the central laboratory for assessment, annually. Those with normal cytology/cytometry 
provided sputum samples the following year. Unless participants formally withdrew from 
the trial, they were asked to provide sputum annually even if they had not done so 
previously. 
 
Specimens obtained via AFB were categorized as positive/abnormal if the cells 
exhibited squamous metaplasia, mild to severe dysplasia, carcinoma in situ or 
carcinoma. LDCT (target radiation dose <2mSv) was conducted without contrast. A 
positive/abnormal LDCT (nodule size ≥9mm) could initiate cancer investigations 
according to local practice. People with both normal AFB and LDCT continued to have 
these tests annually. Individuals with abnormal AFB or LDCT, not indicative of invasive 
cancer, could be seen 4-6 months later, depending on nodule size. Neither group 
provided further sputum samples.  
 
All participants were flagged with established cancer registries (Health & Social Care 
Information Centre in England, and the Northern Ireland Cancer Registry); notifications 
received until April 2018. Research nurses also periodically checked patient records for 
cancer diagnoses. These two sources provided the cancer notifications; stage and 




The primary outcome was the proportion of lung cancers diagnosed at an early stage, 
an endpoint used previously:[32,33] stage I/II for non-small cell lung cancer, or limited 
disease for small cell lung cancer. For completeness, we also examined the proportion 
with advanced lung cancer (post hoc), which might be less influenced by over-
diagnosis. Other endpoints included: uptake of sputum sampling, AFB and LDCT; 
proportion of participants in the surveillance arm with abnormal sputum cytology and/or 
cytometry; number of failed/inadequate sputum samples; and prevalence of pre-
invasive disease among participants with abnormal cytometry/cytology.  
 
The proportion of people with lung cancer who were diagnosed at an early (or 
advanced) stage was compared between the trial arms (relative risk), and also rate ratio 
using person-years. Additional analyses were performed to check consistency in the 
findings. Estimates of screening performance for each test separately were: (i) 
sensitivity (proportion of all lung cancers with positive test results) and (ii) false-positive 
rate (FPR: proportion of all those without lung cancer with positive test results).  
 
Statistical methods 
15% of controls were expected to be diagnosed at an early stage.[32] From prior LDCT 
studies and our pilot study of pre-invasive disease, 80% of cancers were stage I/II,[29] 
so we conservatively used 50%. To detect a difference of 15 vs. 50% required a target 
sample size of at least 37 lung cancers per arm (95% power, and 5% one-sided 
significance test pre-specified for this preliminary study). The expected total proportion 
of prevalent and incident lung cancers was ~6%[9] so to obtain 74 cancers required 




1568 participants (785 screened, 783 controls) were recruited from 10 UK centres 
between August 2007 and March 2011 (Figure 1, Appendix Table 1). Baseline 
characteristics were balanced (Table 1). 
 
Seven centres routinely collected screening logs of people approached: 38.7% of all 
those contacted by telephone after the initial search accepted the invitation to attend the 
pre-trial assessment, of which 42.4% were randomised (Appendix Table 2). The initial 
uptake (38.7%) is high compared to LDCT screening trials, and probably due to our 
focus on COPD patients who might be more aware of smoking-related risks and their 
chronic symptoms influenced their decision to enroll, compared to a more general 
population. Older people were more likely to decline to participate in the trial (odds ratio 
1.92 for ≥70 versus <50 years, p<0.0001). There was no association with gender, but 
there were geographical differences (Appendix Table 3).  
 
 
Provision of sputum samples 
In the first year (baseline), 89.8% provided sputum samples, but 36 were inadequate for 
assessment (so 85.2% provided an evaluable sample). Of those with adequate 
samples, 19.0% were abnormal for either cytology or cytometry, and the rate was lower 
in subsequent years (Table 2). The percentage not providing an adequate sputum 
sample increased from 14.8% at baseline up to 46.1% by year 5. 
 
33.2% of all individuals in the screened arm had an abnormal sputum result at any time, 
of which 22.5% had abnormal cytology, and 12.6% had abnormal cytometry (1.9% 
[15/785] had both abnormal cytology and cytometry, 20.6% [162/785] had abnormal 
cytology only, and 10.7% [84/785] had abnormal cytometry only). 82.4% (14/17) of the 
sputum-positive cancers were detected at an early stage compared to 38.1% (8/21) of 
sputum-negative cancers (p=0.01). Cytology which used morphological criteria alone, 
identified more cancers than image cytometry (12 vs. 5), among those with abnormal 
sputum, so they appeared to be complementary. No cancer had both abnormal cytology 
and cytometry. There was no discernable association between type of sputum test and 
histology, particularly with having only few cases.  
 
Primary endpoint 
78 lung cancers were identified (36 and 42 in the control and screened groups 
respectively); Kaplan-Meier plot in Appendix Figure 2. The median follow-up was 5 
years, matching the planned duration in the protocol for each participant. 
  
Table 3 shows histology and cancer staging. Overall, 54.8% screened versus 45.2% 
controls, with known staging, were diagnosed at an early stage (similar to 59.4% versus 
48.1% for non-small cell lung cancer alone). Table 4 compares stage at diagnosis 
between the trial arms. The relative risk for early stage cancer detection was 1.21 (95% 
CI 0.75-1.95, one-sided exact p=0.24); or 0.82 (95%CI 0.52-1.31) for advanced 
cancers. Hence there was no clear stage shift. In the sensitivity analyses, the rate ratio 
was a secondary analysis (not pre-specified in the trial protocol), and although the 
estimate for early stage disease made screening appear favorable (1.83, 95%CI 0.94-




Table 5 summarizes the findings of all three tests among the lung cancers in the 
screened group: 44.7% had an abnormal sputum sample, but 55.3% (21 cases) had  
normal results for all samples.  
 
Figure 2 summarizes sensitivity and FPR for all three tests, estimated only among 
individuals who actually had the tests (labelled ‘direct’), and among all 785 randomised 
to surveillance (labelled ‘overall’); further description in Appendix Text 4. The measures 
for LDCT and AFB can only be interpreted in the context of being second-stage tests, 
and do not represent performance for population screening where everyone has the 
test(s). 
 
In the screened group, the overall sensitivity for sputum was 40.5% and FPR 32.8%. 
When examining only those who had sputum results, the direct sensitivity for 
cytology/cytometry was 44.7%, and corresponding FPR 38.7% (Figure 2). Hence, 
sputum testing did not detect many cases. The direct FPR at baseline only was 18.7%, 
and lower in the subsequent year 13.2%. Sputum testing had insufficient screening 
performance. 
 
188 individuals had an AFB at any time during the trial (an additional 73 declined or did 
not attend; uptake 72.0%). Only 11 sputum-positive cancer cases had AFB, and the 
direct sensitivity was 45.5%, with high FPR 39.5% (Figure 2). Among participants with 
abnormal sputum, 38% had pre-invasive disease (72/188 mild to severe dysplasia or 
metaplasia); only 3 of these (2 moderate dysplasia and 1 squamous metaplasia), later 
developed lung cancer. 
 
239 individuals had a LDCT at any time during the trial (an additional 22 declined or did 
not attend; uptake 91.6%). Sixteen sputum-positive cancer cases had LDCT, and the 




Other cancers, mortality and smoking status 
Appendix Table 4 summarizes the end of trial status, including the number who had an 
exit chest radiography (430 screened and 486 controls, so unlikely to have biased the 
cancers found). Other cancer types were balanced between the two groups. Lung 
cancer mortality (16 screened vs. 21 controls, hazard ratio 0.86, p=0.65), and all-cause 
mortality (hazard ratio 0.87, p=0.39) were similar; Appendix Figure 3. Among those who 
were current smokers at baseline (with known smoking status at 5 years), 15.0% 
controls and 17.7% screened individuals had stopped completely during the trial.  
 
Adverse events 
In the surveillance group, one person had a COPD exacerbation possibly linked to AFB, 





We examined a sequential approach to only offer LDCT and AFB as second screening 
tests among particularly high-risk individuals with abnormal sputum cytology/cytometry. 
Had we found a substantial stage shift a larger randomised trial of lung cancer mortality 
would overcome lead-time bias and over-diagnosis. LungSEARCH complements LDCT 
trials,[2,6] including the only other randomised trial of lung cancer screening conducted 
in the UK (UKLS).[33] 
 
Although LungSEARCH preceded NLST and NELSON,[5,6] the concept that an 
effective, cheap and easy initial test (sputum) could be considered for a wider group of 
smokers than is currently eligible for LDCT remains valid. This is because current 
criteria excludes many high-risk people. Applying USPSTF criteria,[7] 25% of the 
LungSEARCH participants would be ineligible for LDCT. We hoped, therefore, that our 
sequential approach could find many cancers without offering many more LDCT scans.  
 
We exceeded the target of 50% of lung cancers diagnosed at an early stage using our 
surveillance strategy (observed 55%), but the lack of effect was driven by the high 
percentage of unscreened participants diagnosed at early stage (45% observed instead 
of 15% expected when LungSEARCH was designed in 2006). Prominent health 
campaigns encourage people with persistent cough to seek medical attention sooner, 
explaining why more lung cancers are now diagnosed earlier, as seen in UK audit 
data.[34] Although we reached the target sample size and hence had power for the 
expected primary outcome (50 vs 15% early stage cancers), the observed small stage 
shift of 55 versus 45% is not worthwhile clinically. 
 
In LungSEARCH, 90% of those who attempted a sputum sample did so successfully. 
However, an increasing number of people did not provide sputum over time, and 4 lung 
cancers were among participants who provided no samples. Hence, 60% of all lung 
cancers in the screened group did not have the opportunity for earlier detection by 
LDCT. Furthermore, of the cancers with sputum samples, only 45% had abnormal 
results (referred for LDCT and AFB). This is lower than the expected 80% from a study 
that had more males than LungSEARCH and 59% had moderate/severe cough, though 
in that study the sensitivity of sputum decreased to 21% for stage I 
adenocarcinoma.[21] It is unclear why sputum was not effective. Unlike cervical cancer 
screening which involves active removal of cells in the cervix, detecting lung cancer in 
sputum depends on cells naturally shed into the bronchi, which is influenced by tumour 
location and histology. It could be that malignant cells in the early stages of lung cancer 
are still anchored to the basement membrane and each other, so that not enough travel 
into the lumen. Although sputum testing has the appeal of being conducted at home, 
avoiding travel to screening clinics which is required by LDCT (especially from rural 
areas), the lower number of individuals who provided samples from year 2 plus the fact 
that several samples are inadequate together makes sputum testing less useful than 
LDCT in which a result could be obtained in almost all cases who are scanned. 
 
AFB uptake was not high (72%), because several participants informed us that they 
found AFB off-putting or uncomfortable.[35] Systematic reviews of AFB show 
heterogeneous study designs and variable sensitivities (67-100%),[37-39] Whilst AFB 
has value for people presenting with symptomatic lung problems, LungSEARCH 
suggests a limited role in screening. Improvements in the optics in videobronchoscopes 
have reduced the need for the fluorescence mode, and the shift in the natural history of 
lung cancer from central to more peripheral tumours further limits the utility of AFB. 
 
Very few reports have examined lung cancer screening in COPD. The NLST sub-study 
(ACRIN) indicated a shift towards early stage cancer among COPD participants who 
had LDCT compared to those who had chest radiography,[40] but no reduction in lung 
cancer deaths.[41] The Danish Lung Cancer Screening Trial hinted that COPD 
participants with >35 pack-years might benefit from LDCT.[42] Whereas in a non-
randomised matched cohort study of mild to moderate COPD, 80% of lung cancers in 
those who had LDCT were diagnosed at stage I versus 0% among those without LDCT; 
corresponding lung cancer deaths of 1 vs. 12 (p=0.002).[43] 
 
Our trial had limitations. As in all cancer screening trials, participants cannot be blinded, 
hence the potential for bias (e.g. controls were aware of the trial objectives possibly 
making them more alert to symptoms and seeking medical advice sooner) which might 
contribute to the higher than expected proportion of early stage cancers. Similarly, 
participants who stopped having the screening tests earlier might lead to a lower 
percentage diagnosed with early stage cancer. We had no data on cancer treatments 
nor retrieved histological specimens for central pathology review, as these required 
additional local resources. Over-diagnosis bias is an established issue in studies 
examining stage shift. We found slightly more lung cancers in the screened group (42) 
than controls (36), and the different denominators (expected in screening studies) can 
influence the comparison of stage shift. Therefore, we allowed longer time for cancer 
notifications from the registries and to arrange the exit chest radiographs in the controls. 
Although we did not find a material difference in cancer stage in LungSEARCH, there is 
some evidence that people with COPD tend to develop more aggressive lung 
cancers,[44-45] and the NLST suggests that over-diagnosis from LDCT screening is 
only seen in people with normal lung function, not in COPD, though this should be 
confirmed in other studies.[40] Finally, we did not know whether some of the control 
group participants had LDCT during the trial, which might have reduced the effect of our 
screening policy, though we expect this to be very few because LDCT is not 
recommended routinely. 
 
LDCT screening can be made more efficient using risk algorithms (including age and 
smoking intensity), where only those with a risk exceeding a specified cut-off are offered 
LDCT. Such models detect more lung cancers with fewer false-positives than current 
criteria.[7] Several risk calculators contain COPD as a factor,[46-48], and 
demonstration/pilot studies in the UK conclude that the Liverpool Lung Project risk 
model and/or the PLCO2012 model should be used to identify high-risk population in 
screening programmes.[49-52] These recommendations are supported by 
LungSEARCH in which LDCT detected all lung cancers among sputum-positives 
(though we cannot tell how well LDCT would have performed in the sputum-negative 
cases, and our trial did not include people without COPD). 
 
In conclusion, our sequential screening strategy did not show a stage shift in cancer 
diagnosis. Our trial has implications for future research and practice. First, it provides 
evidence from a large randomised trial that it is difficult to find ways of targeting LDCT 
screening to make it more efficient (other than risk-based algorithms). LDCT should 
therefore be offered to all eligible individuals within planned screening programmes. 
Second, our study was based on particularly high-risk individuals (smokers with COPD) 
and many unscreened individuals (controls) were diagnosed at an early cancer stage, 
indicative of them seeking medical attention sooner, in line with UK audit data. This 
probably means that this group are more receptive to screening and early detection, 
such that the uptake of LDCT within organised programmes could be high among them. 
Third, LDCT detected all lung cancers among COPD patients in our trial who were 
sputum-positive, which is suggestive evidence that planned screening programmes 
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Sex:   
    Female 373 (48%) 377 (48%) 
    Male 410 (52%) 408 (52%) 
   
Smoking status:   
    Current 435 (56%) 439 (56%) 
    Former 348 (44%) 346 (44%) 
   
COPD severity:   
    Mild 195 (25%) 196 (25%) 
    Moderate 588 (75%) 588 (75%) 
    missing/unknown 0 1 
   
Source of participants:   
    General practice 622 (79%) 619 (79%) 
    Pulmonary rehabilitation program 95 (12%) 94 (12%) 
    Hospital outpatients 35 (4%) 42 (5%) 
    Lung function laboratory 31 (4%) 30 (4%) 
   
 Mean Mean 
Age at randomisation (years) 63  63 
Age when started smoking 16 16 
Age when stopped smoking 61 (n=348) 62 (n=346) 
   
Number of cigarettes smoked per day 24 24 
Number of years of smoking 45 45 
Pack years 53 54 





Table 2. Sputum results in the screened group in each year 
 
 Baseline Year 2 Year 3 Year 4 Year 5 
      
Cytology or cytometry result
1
 N=785* N=639* N=560* N=516* N=447* 
    Normal 542 (81%) 398 (87%) 343 (94%) 300 (89%) 221 (92%) 
    Abnormal - low grade 111 (17%) 51 (11%) 18 (5%) 33 (10%) 17 (7%) 
    Abnormal - high grade 16 (2%) 6 (1%) 2 (1%) 4 (1%) 3 (1%) 
    Died or cancer diagnosed since last visit N/A 19 22 24 32 
    No sputum result 116 (15%)# 184 (29%)# 197 (35%)# 179 (35%)# 206 (46%)# 
          Did not provide sample 68 131 155 157 195 
          Tried but unable to provide sample 12 10 3 8 5 
          Provided spontaneous sample
2
 33 43 38 14 6 
          Provided induced sample
2
 3 0 1 0 0 
      
Cytology result (where available) N=604 N=400 N=301 N=285 N=198 
    Normal 503 (83%) 358 (90%) 289 (96%) 269 (94%) 191 (96%) 
    Abnormal - low grade 86 (14%) 36 (9%) 11 (4%) 13 (5%) 5 (3%) 
    Abnormal - high grade 15 (2%) 6 (2%) 1 (<1%) 3 (1%) 2 (1%) 
      
Cytometry result (where available) N=603 N=418 N=350 N=323 N=237 
    Normal 570 (95%) 400 (96%) 342 (98%) 298 (92%) 221 (93%) 
    Abnormal - low grade 32 (5%) 18 (4%) 7 (2%) 22 (7%) 15 (6%) 
    Abnormal - high grade 1 (<1%) 0 1 (<1%) 3 (1%) 1 (<1%) 
      
 
The percentages in brackets for normal or abnormal sputum are based on the total number who had a sputum result 
as the denominators. 
 
* These are the total number of people expected to provide sputum samples in each year (i.e. excluding those who 
had an abnormal sputum result, died or were diagnosed with cancer who were no longer expected to provide sputum 
samples) 
 
#These represent the percentage who did not provide a sputum sample, out of the total expected 
 
1. In some cases only cytology or cytometry results were available (not both), and so the result classification was 
based on the known result if a repeat sputum sample was not done. 














   
Small cell 5 (14%) 10 (24%) 
Adenocarcinoma 8 (22%) 11 (26%) 
Squamous 9 (25%) 14 (33%) 
Large cell 0 1 (2%) 
Other histology 9 (25%) 5 (12%) 
Unknown 5 (14%)
2
 1 (2%) 
   





    Stage I 11  16 
    Stage II 2 3 
    Stage III 6 4 
    Stage IV 7 9 
    Unknown 1  
   
Small cell lung cancer: N=5 N=10 
    Limited disease 1 4 
    Extensive disease 4 6 
   
 
1. Includes 1 patient in each trial group where histology was unknown but stage was available 
 
2. Diagnosed at non-trial sites (unknown, or not set up for the trial so no access to medical records). 
These cancers were notified through registries, and we found staging for one of the 5 cases. 
 
The exit chest radiography found 5 cancers in the screened group (these had no sputum samples or their 
sputum tests were normal throughout the trial: cancer stage was I [n=2], II [n=1], IV [n=1]) and limited 







Table 4. Comparison of stage at diagnosis among those with lung cancer (in total there were 42 and 36 lung cancers in the screened and control arms 
respectively) 
      
 Primary outcome measure    
 Early stage disease (I/II for non-small cell 
and limited disease for small cell cancer) 
 Advanced disease (III/IV for non-small cell 
and extensive disease for small cell cancer) 
 Screened Controls  Screened Controls 
Main analysis  
(cancer cases with known stage) 
54.8% (23/42) 45.2% (14/31)  45.2% (19/42) 54.8% (17/31) 
Relative risk 1.21 (95%CI 0.75-1.95, p=0.24)  Relative risk 0.82 (95%CI 0.52-1.31, p=0.24) 
      
Sensitivity analyses:      
All cancers included in the 
denominators 
54.8% (23/42) 38.9% (14/36)  45.2% (19/42) 47.2% (17/36) 
Relative risk 1.41 (95%CI 0.86-2.30, p=0.09)  Relative risk 0.96 (95%CI 0.59-1.55, p=0.50) 
      
Excluding cancers found by the exit 
chest x-ray 
(5 screened; 6 controls) 
51.3% (19/37) 42.3% (11/26)  48.9% (18/37) 57.8% (15/26) 
Relative risk 1.21 (95%CI 0.70-2.09, p=0.30)  Relative risk 0.84 (95%CI 0.53-1.35, p=0.30) 
      
Cancer incidence expressed as 
person years** 
6.8 per 1000  3.7 per 1000 
 
 5.6 per 1000  4.5 per 1000 
 
Rate ratio 1.83 (95%CI 0.94-3.54, p=0.049)  Rate ratio 1.24 (95%CI 0.65-2.39, p=0.31) 
      
Cancer incidence expressed as 
person years, & excluding cancers 
found by the exit chest x-ray 
5.7 per 1000 3.0 per 1000 
 
 5.4 per 1000  4.0 per 1000 
 
Rate ratio 1.92 (95%CI 0.91-4.03, p=0.049)  Rate ratio 1.33 (95%CI 0.67-2.64, p=0.24) 
      
 
*P-values are one-sided (specified in the protocol) because of interest only in finding more early stage cancers in the screened arm. LungSEARCH is not a definitive assessment of 
a screening policy, so it is analogous to phase II treatment trials which commonly use one-sided statistical tests. 
 
Rate ratio, which uses person-years, might be less affected by overdiagnosis and unknown disease stage in the denominators 
Relative risk or rate ratio of >1 for early stage indicates that screening was effective (more early stage disease found in the screened group). 




Table 5. Test findings among all 42 lung cancers in the screened group 
 
Test results  
  
Sputum result N=38  
    Abnormal 17 (80 
    Normal 21 (55%) 
    No sputum or both cytology/cytometry inadequate 4 
Cytology result  
    Abnormal 12 (32%) 
    Normal 26 (68%) 
Cytometry result  
    Abnormal 5 (13%) 
    Normal 33 (87%) 
  
Worst AFB result: N=11 
    Carcinoma 2 (18%) 
    Moderate dysplasia 2 (18%) 
    Squamous metaplasia 1 (9%) 
    No abnormality 6 (55%) 
  
Sputum and LDCT results: N=42 
No sputum samples (hence no LDCT) 4 [2]1 
Sputum normal throughout study (hence no LDCT) 21 [3]1 
Sputum abnormal, LDCT detected cancer directly afterwards2 8 
Sputum abnormal, LDCT detected cancer at a later follow-up3 7 
Sputum abnormal, LDCT did not flag for cancer investigation4 1 
Sputum abnormal, but no LDCT done 1 
 
 
1. The numbers in square brackets are lung cancers found by the exit chest radiography at 5 years 
2. The abnormal sputum result led directly to an abnormal CT (i.e. a nodule ≥9mm), and the individuals were 
referred for immediate diagnostic investigations 
3. Individuals had an abnormal sputum, and the abnormal CT that found the cancer was one of the later follow-up 
scans. In 3 cases, the first CT with a nodule ≥9mm was some years before the cancer diagnosis but subsequent 
CTs indicated that the nodule had shrunk before the final CT that led to diagnostic investigations showed nodule 
growth. 
4. Individual had normal annual CT scans during the trial. The cancer was found by a CT scan given outside of the 



































Figure 1. CONSORT diagram 
*It transpired that one person actually had lung cancer >1 year prior to randomisation but did not inform the trial staff 
(they would have been ineligible). Because this was only discovered at the end of the trial (cancer notification by the 
national registry), the person is kept in the intention-to-screen analyses. The person had normal sputum samples 
throughout, and no AFB or CT (and not counted as a cancer case). Counting this as a cancer case has only a small 
effect on sensitivity (44.7% without it [Figure 2] and 43.6% with it). 
**Even though some participants withdrew from the trial procedures before 5 years, they were still flagged for cancer 
occurrence. 
Appendix Table 1 provides further details about number of participants approached and trial uptake 
1568 participants with COPD 
August 2007 – March 2011 
 
Surveillance arm (n=785)* 
5 years annual sputum screen. 
If either sputum cytology or cytometry 
show abnormalities, participants then have 
annual autoflorescence bronchoscopy and 
low dose CT (frequency of CT depends on 
the nodule assessment). 
Those with normal sputum had annual 
sputum tests 
Randomisation: 
stratified according to site, age, gender, 
COPD severity and smoking history 
 
Control arm (n=783) 
5 years usual clinical follow-up 
 
Exit chest radiography at 5 years or earlier if 
participants decided to leave the study 
Control arm 
 
Early withdrawal, n=70:** 
51 lost to follow-up 
13 subject choice 
6 reasons unknown 
 
Lung cancer diagnosis (primary 
outcome): 36 
 
Surveillance arm  
 
Early withdrawal, n=145:** 
48 lost to follow-up 
95 subject choice 
2 reasons unknown 
 








Figure 2. Summary of screening performance for the three tests in the surveillance group, based 
on results at any time during the trial. Sensitivity (sens.): % of cancers with abnormal results, and 
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Appendix Text 1. Further details of the sputum sampling 
 
Individuals in the screened group provided annual sputum samples (three 
pots) at home. Samples were posted to the central laboratory at University 
College London Hospital, who prepared four slides using Thin-Prep-2000 
processor (Cytyc UK). Two had Papanicolaou staininga for cytology review, 
and two were stained with a modified Feulgen’s reagentb for cytometry. 
 Cytology samples were considered assessable if each contained ≥5 
alveolar macrophages and/or bronchial cells. Morphological 
parameters were graded using the Bethesda classification systemc for 
Squamous Intraepithelial Lesions (SIL). The presence of any atypia, 
either low- or high-grade SIL was considered ‘abnormal’. 
 Cytometry: a semi-automated system was used (Fairfield DNA ploidy, 
Fairfield Imaging, Nottingham, UK), in which DNA histograms were 
examined and samples classified as having normal or abnormal DNA 
contents using published criteria.d 
 
a. Papanicolaou GN. A new procedure for staining vaginal smears. Science. 1942; 95: 438–
439. 
 
b. Schulte E, Wittekind DH. Standarization of the Feulgen reaction: the influence of chromatin 
condensation on the kinetics of acid hydrolysis. Annal Cell Pathol 1990; 2:149–157. 
 
c. Solomon D, Nayar R. The Bethesda System for Reporting Cervical Cytology. Definitions, 
Critera and Explanatory Notes., 2
nd
 ed. Springer Verlag, New York;2004:1-191. 
 
d. Sudbo J, Kildal W, Risberg B, Koppang HS, Danielsen HE, Reith A.  DNA content as a 
prognostic marker in patients with oral leukoplakia. N Engl J Med. 2001;344:1270-8. 
  
 
Appendix Text 2. Further details of auto-florescence bronchoscopy 
(AFB) 
 
Delivery of AFB 
 
AFB was performed under conscious sedation, and the bronchial tree 
examined under different lights using optical filters incorporated into the 
bronchoscope (D-light auto-fluorescence system, Karl Storz Gmbh, Germany; 
or auto-fluorescence video-bronchoscope, Olympus Medical, Japan). If AFB 
appeared abnormal under either white or blue light, 1-3 bronchial biopsies (for 
histology review) were taken from each affected area, and also an area with 
normal appearance on the contralateral side. For individuals without an 
abnormality, three biopsies were taken from a single area of normal 
appearance. Specimens were reviewed locally by an expert pulmonary 
histopathologist, categorized as squamous metaplasia, mild to severe 
dysplasia, carcinoma in situ or carcinoma. 
 
 
Categories of dysplasia using AFB and subsequent histopathology: 
1 = Squamous metaplasia 
2 = Mild dysplasia 
3 = Moderate dysplasia 
4 = Severe dysplasia 
5 = Carcinoma-in-situ 
6 = Carcinoma 
 
If no pre-invasive lesion were found after histopathology review of the bronchial 
biopsy tissue samples, AFB was repeated annually. 
 
If a pre-invasive lesion were found by histopathology, AFB was repeated at intervals 
according to the grade of pre-invasive lesion:  
 for carcinoma in situ and severe dysplasia (categories 4-5) the interval could be 
approximately 5 months  
 for moderate to mild dysplasia (categories 2-3) the interval would be 
approximately 8 months. 
 
If an invasive lesion (category 6) were found the individual was referred for other 






Appendix Text 3. Further details of the low dose CT scan (LDCT) 
 
 
LDCT (target radiation dose <2mSv) was conducted without contrast, and 
assessment of nodules largely determined the frequency of subsequent 
follow-up using LDCT. Suspicion of cancer (a nodule size ≥9mm) could lead 
directly to CT with contrast, PET/CT or other investigations for cancer 
according to local practice. 
 
LDCT delivery 
  No Intravenous contrast for initial scan 
o Width section needs to be 1mm or equivalent with a multi-detector row 
CT scanner  
o Axial +/- coronal reformats if available [Review MIPs  from work 
stations  if available ] 
o Low dose CT equivalent   [depending on local practice /Dose 
modulation CT packages available, and patient’s habitus].  Standard 
dose for CT scan if the nodule demonstrates growth or suspicious 
features with IV contrast. 
o Images viewed from computer workstations with standard lung / soft 
tissue and bone settings. 
 
Assessment of Nodules   
 Document for non-calcified nodules 
1. Anatomical site 
2. Size-Volume assessment with maximum diameter all three planes.  Growth of 
>25% is considered significant and further follow-up required       
3. Morphology: 
o Round or oval 
o Smooth or irregular margin 
o Solid or ground glass /  semisolid   
o +/- cavitation 




Those with mass lesions suspicious for lung cancer underwent urgent investigations 
as deemed appropriate by their clinician. Indeterminate non-calcified nodules were to 




Recommended frequency of CT 
scan 
 
< 5 mm Annually 
Follow-up non contrast-enhanced CT, to 
look for growth. 
≥ 5 to < 7 mm At 6, 12 and 18-24 months 
Follow-up non contrast-enhanced CT. 
If growth assess with IV contrast. 
≥ 7 to < 9 mm At 4, 8, 12 and 24 months 
Follow-up non contrast-enhanced CT. 
If growth assess with IV contrast. 
≥ 9 mm 
(a) If nodule appears benign: CT at 
4, 8, 12 and 24 months 
 




Follow-up (IV) contrast-enhanced CT. 
 
 
For malignant-looking nodules: 
investigate for cancer with dynamic CT,  
PET/CT, biopsy, FNA, or surgery, as 
indicated by local practice. 
 
a. Henschke CI, McCauley DI, Yankelvitz DF et al. Early detection lung project: overall 
design and findings from baseline screening. Lancet 1999;354:99-105. 
b. Swensen SJ, MD, Jett JR, Sloan JA, et al. Screening for lung Cancer with low dose 
helical computed tomography. Am J Respir Crit Care Med. 2002; 165:508-513. 
c. Pastorino U, Bellomi M, Landoni C, et al., Early lung-cancer detection with spiral CT and 
positron emission tomography in heavy smokers: 2-year results Lancet 2003;362:593–97. 
d. Fleischner society, Radiology 237, 2,395-400 2005 
 
 
Central quality control audit 
Two chest radiologists at UCLH (not managing trial patients) conducted independent 
quality assurance audits between April 2009 and July 2014. Double blind reviews of 
randomly selected LDCT scans retrieved from all sites were carried out, and the 
LDCT case report forms (CRFs) were also audited. Early in the trial, double reporting 
of scans at each site was undertaken, contributing to delays in sending the data to 
the trials centre. The independent review confirmed a high concordance between 
local reports, so that single reporting was implemented for the remainder of the trial 
(which consequently improved CRF return). The central review demonstrated a delay 
between a positive sputum result and having a LDCT in some cases, successfully 
leading to a change in practice which minimized/avoided the delay. The central 
review resulted in the same outcomes of the scans (i.e. cancer referral or timing of 






Appendix Text 4. Description of screening performance for the 3 tests 
used (sputum, AFB and LDCT) 
 
33.2% (261/785) of all individuals in the screened arm had an abnormal 
sputum result at any time, of which 22.5% (177/785) had abnormal cytology, 
and 12.6% (99/785) had abnormal cytometry. Among these 261, only 15 had 
both abnormal cytology and cytometry (162 abnormal cytology alone and 84 
abnormal cytometry alone). 38 of all lung cancers in the screened group had 
sputum results, and 17 were abnormal at some point: 12 abnormal cytology 
alone and 5 abnormal cytometry alone (Table 5).  
 
Table 5 shows that 21 lung cancer cases had a normal sputum throughout 
and were diagnosed outwith the trial procedures (4 adenocarcinoma, 5 
squamous, 8 small cell, 1 large cell, and 3 other types). 8 (38.1%) were at an 
early stage, much lower than among the 17 cases that had an abnormal 
sputum, where 14 were diagnosed at an early stage (82.4%) and all were 
found by LDCT. Among the 3 cases with abnormal sputum diagnosed at late 
stage, two were found by LDCT directly following the abnormal sputum result, 
and the other case had neither an AFB nor LDCT. 
 
No cancer had both abnormal cytology and cytometry. There was no 
discernable association between type of sputum test and histology, 
particularly with having only few cases.  
 
When examining only those who had sputum results, the direct sensitivity was 
44.7% (17/38), and corresponding FPR 38.7% (244/631); Figure 2. When 
considering all 42 lung cancers found and all 743 individuals without lung 
cancer, the overall sensitivity was 40.5%, and FPR 32.8%. These are 
cumulative FPRs by year 5. The direct FPR at baseline only was 18.7% 
(118/631) and in the subsequent year only it was 13.2% (55/417). 
 
188 individuals had an AFB at any time during the trial (an additional 74 
declined or did not attend; uptake 71.7% [188/188+74]). Of these, 39.9% 
(75/188) were abnormal (metaplasia, dysplasia, carcinoma or carcinoma in 
situ). The overall prevalence of pre-invasive disease among participants with 
abnormal sputum was 38% (72/188 had mild to severe dysplasia or 
metaplasia; but only 3 of these [2 moderate dysplasia and 1 squamous 
metaplasia], later developed lung cancer, 2.3-10.1 months later). Of the 17 
lung cancers who had abnormal sputum, 6 never had AFB; whilst 11 did, of 
which 5 had suspicious lesions/dysplasia: direct sensitivity 45.4% and FPR 
39.5% (Figure 2). Two of these 5 were confirmed as cancer after 
histopathology review (Table 5), where one was visualized by AFB on the 
right main bronchus (missing information for the other). For two other cases, 
AFB appeared normal but histopathology of the biopsy taken exhibited 
dysplasia.  
 
239 (30.4%) individuals had a LDCT at any time during the trial (an additional 
22 declined or did not attend; uptake 91.6% [239/239+22]). Of these, 21.8% 
(52/239) had at least one nodule of ≥9mm, considered for immediate 
diagnostic investigation. 18.8% (45/239) had nodules between 5 and 9mm, 
requiring LDCT scans more regularly than annually, but no immediate cancer 
investigations, and none of these 45 were diagnosed with lung cancer during 
the study. Among all 42 lung cancers, 16 had a LDCT (Table 5), of which 15 
had an abnormal finding (nodule ≥9mm) during the trial and then referred for 
cancer diagnoses, and the other case was found by LDCT performed at trial 
exit (a nodule ≥9mm). Figure 2 shows that the direct sensitivity was 100%; 











    Chelsea & Westminster 348 (22%) 
    Cambridge 301 (19%) 
    University College Hospital London 277 (18%) 
    Leeds 206 (13%) 
    Belfast 106 (7%) 
    Leicester 89 (6%) 
    Royal Brompton 75 (5%) 
    Manchester 65 (4%) 
    Coventry 61 (4%) 
    Sunderland 40 (3%) 







Appendix Table 2. Summary of recruitment activity among the 7 centres 
that had screening logs 
 
       







who did not 
reply 
 
 Declined to 
participate 
Accepted Number who 
were 
randomized# 
UCH 1580 400 (25%)  470 (30%) 710 (45%) 277 
Brompton 225 67 (30%)  39 (17%) 119 (53%) 75 
Chelsea & Westminster      
   Hospitals 64 5 (8%)  19 (30%) 40 (62%) 4 
   GPs 2437 368* (15%)  1003* (41%) 1066* (44%) 344 
Cambridge 1368 212 (15%)  738 (54%) 418 (31%) 301 
Leeds 1622 362 (22%)  709 (44%) 551 (34%) 206 
Belfast 702 343 (49%)  164 (23%) 195 (28%) 106 
       
Total 7998 1757 (23%)  3142 (39%) 3099 (39%) 1313** 
*approximate 
** 1568 in total in the trial 
# out of those who accepted the invitation and were eligible after baseline tests 
 
 
39% (3099/7998) of all those contacted by telephone after the initial search 
accepted the invitation to attend the pre-trial assessment, of which 42% 




Appendix Table 3. The odds ratio (95% CI) of declining to participate in 
LungSEARCH according to geographical location (centre), age and sex. 
 
Factor Univariable (based on 








missing data for all 3 
factors)* 
    
Location:    
No. subjects 4327 3747 3747 
No. who declined 2974 2394 2394 
UCH 1.0 1.0 1.0 
Brompton 0.83 (0.56-1.23) 0.31 (0.16-0.58) 0.29 (0.15-0.55) 
Chelsea & 
Westminster 
1.07 (0.85-1.35) 0.76 (0.57-1.00) 0.74 (0.56-0.98) 
Cambridge 3.65 (2.94-4.54) 5.71 (4.49-7.26) 5.41 (4.25-6.90) 
Leeds 5.94 (4.72-7.48) 9.57 (7.45-12.30) 9.63 (7.47-12.41) 
Belfast 1.27 (0.93-1.75) 2.01 (1.44-2.81) 2.01 (1.43-2.81) 
Sunderland 9.52 (6.56-13.81) 3.41 (2.21-5.28) 3.63 (2.34-5.64) 
 P<0.0001 P<0.0001 P<0.0001 
    
Age:    
No. subjects 3755 3747 3747 
No. who declined 2402 2394 2394 
Age  <50 years 1.0 1.0 1.0 
 50-59 1.95 (1.47-2.59) 1.96 (1.48-2.60) 1.27 (0.92-1.76) 
 60-69 1.84 (1.41-2.39) 1.85 (1.42-2.41) 1.22 (0.90-1.65) 
 70+ 2.53 (1.92-3.34) 2.54 (1.93-3.35) 1.92 (1.40-2.63) 
 P<0.0001 P<0.0001 P<0.0001 
    
Sex:    
No. subjects 4300 3747 3747 
No. who declined 2947 2394 2394 
 Males 1.0 1.0 1.0 
 Females 1.10 (0.96-1.25) 1.13 (0.99-1.29) 1.02 (0.88-1.19) 
 P=0.16 P=0.08 P=0.80 
    
*Odds ratios are adjusted for the other two factors in the table 
 
Univariable and multivariable logistic regressions were used to examine the odds of 
declining to participate (adjusted for age, sex and geographical location). This 
information could be used to consider potential factors that might influence future 
lung screening uptake in the UK (acknowledging that here, people were asked for 
participation in a randomized study of screening, rather than screening per se). 
People from Belfast, Cambridge, Leeds and Sunderland were more likely to decline 
than those from the University College London Hospital area (odds ratios of 2.01, 
5.41, 9.63 and 3.63 respectively), while those from the Brompton Hospital and 
Chelsea and Westminster areas were less likely to decline (odds ratios of 0.29 and 
0.74 respectively). The reasons for these geographical differences are unclear, but 
might include different approaches to recruitment by staff. However, this does not 
explain the difference in participation between UCH and the Brompton because the 















   
Lung cancer 36 (5%) 42 (5%) 
Other cancers  51 (7%) 47 (6%) 
Deaths 96 (12%) 70 (9%) 
    Lung cancer 21 16 
    Other cancer 17 14 
    All other causes 48 38 
    Unknown cause 10 2 
   
Smoking status:   
    Current smoker that continued 242 (31%) 220 (28%) 
    Current smoker that reduced 46 (6%) 55 (7%) 
    Current smoker that stopped 51 (7%) 59 (8%) 
    Ex-smoker no change 284 (36%) 277 (35%) 
    Ex-smoker re-started 7 (1%) 3 (0%) 
    unknown/missing 153 (20%) 171 (22%) 
   
   
Exit chest radiography:   
    At end of 5 years 451 393 
    Before 5 years (among 
withdrawals) 
35 37 
   
 
 
Because the hospital respiratory units recruited trial participants and so had an interest in the 
study through their lead clinical investigator, it is possible they were more proactive with 
managing these particular participants. However, the percentage of lung cancers found 
among those recruited from general practice/family physicians (4.6%, 57/1241) did not 
















Appendix Figure 2. Kaplan-Meier plot for the incidence of lung cancer. 
The apparent increase in the risk of lung cancer diagnosis after 5 years is mainly due 
to the size of the steps in the Kaplan-Meier plot being exaggerated because there are 
relatively few individuals followed up for this long, with very few events. The trial 
protocol specified 5 years follow up, a few patients appeared to have longer than this 









Appendix Figure 3. Kaplan-Meier plots for deaths due to lung cancer (upper), 
and all cause mortality (lower) 
 
